Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of clinical practice in the United States

Bibliography

• Howlader N, Noone A, Krapcho M, et al. editors. Cancer of the Kidney and Renal Pelvis - SEER Stat Fact Sheets. National Cancer Institute, Bethesda, MD; 2010. Available from: http://seer.cancer.gov/statfacts/html/kidrp.html [Last accessed 25 June 2013]
   Google Scholar
• Tang PA, Vickers MM, Heng DYC. Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far. Hematol Oncol Clin North Am 2011;25(4):871-91
   PubMedGoogle Scholar
• Moons KGM, Royston P, Vergouwe Y, et al. Prognosis and prognostic research: what, why, and how? BMJ 2009;338:b375
   PubMed Web of Science ®Google Scholar
• Motzer BRJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20(1):289-96
   PubMed Web of Science ®Google Scholar
• Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 1984;2(3):187-93
   PubMed Web of Science ®Google Scholar
• Crooks V, Waller S, Smith T, et al. The use of the Karnofsky Performance Scale in determining outcomes and risk in geriatric outpatients. J Gerontol 1991;46(4):M139-44
   Google Scholar
• Heng DYC, Xie W, Regan MM, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 2013;14(2):141-8
   PubMed Web of Science ®Google Scholar
• Negrier S. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d’Immunotherapie. Ann Oncol 2002;13(9):1460-8
   PubMed Web of Science ®Google Scholar
• Mekhail TM, Abou-Jawde RM, Boumerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005;23(4):832-41
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004;22(3):454-63
   PubMed Web of Science ®Google Scholar
• Patil S, Figlin RA, Hutson TE, et al. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol 2011;22(2):295-300
   PubMed Web of Science ®Google Scholar
• Heng DYC, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009;27(34):5794-9
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;116(18):4256-65
   PubMed Web of Science ®Google Scholar
• Manola J, Royston P, Elson P, et al. Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. Clin Cancer Res 2011;17(16):5443-50
   PubMed Web of Science ®Google Scholar
• Bamias A, Tzannis K, Beuselinck B, et al. Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration. Br J Cancer 2013;109(2):332-41
   PubMed Web of Science ®Google Scholar
• Iacovelli R, Farcomeni A, Sternberg CN, et al. Prognostic factors in patients receiving third-line targeted therapy for metastatic renal cell carcinoma. J Urol 2014. [Epub ahead of print]
   Google Scholar
• Harshman LC, Kroeger N, Rha SY, et al. First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium. Clin Genitourin Cancer 2014;12(5):335-40
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Garcia JA, Elson P, et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 2007;110(3):543-50
   PubMed Web of Science ®Google Scholar
• Esbah O, Demirci U, Helvaci K, et al. Sequential therapy and prognostic factors in metastatic renal cell carcinoma: single centre experience. J BUON 2014;19(4):1062-9
   PubMedGoogle Scholar
• De Lichtenberg TH, Hermann GG, Rørth M, et al. Overall survival after immunotherapy, tyrosine kinase inhibitors and surgery in treatment of metastatic renal cell cancer: outcome of 143 consecutive patients from a single centre. Scand J Urol 2014;48:379-86
   PubMed Web of Science ®Google Scholar
• Cetin B, Afsar B, Deger SM, et al. Association between hemoglobin, calcium, and lactate dehydrogenase variability and mortality among metastatic renal cell carcinoma. Int Urol Nephrol 2014;46(6):1081-7
   PubMedGoogle Scholar
• Schutz FAB, Xie W, Donskov F, et al. The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium. Eur Urol 2014;65(4):723-30
   PubMed Web of Science ®Google Scholar
• Stenman M, Laurell A, Lindskog M. Prognostic significance of serum albumin in patients with metastatic renal cell carcinoma. Med Oncol 2014;31(3):841
   PubMed Web of Science ®Google Scholar
• Soerensen A V, Donskov F, Hermann GG, et al. Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: results from the Danish Renal Cancer Group (DARENCA) study-2. Eur J Cancer 2014;50(3):553-62
   PubMedGoogle Scholar
• Amato RJ, Flaherty A, Zhang Y, et al. Clinical prognostic factors associated with outcome in patients with renal cell cancer with prior tyrosine kinase inhibitors or immunotherapy treated with everolimus. Urol Oncol 2014;32(3):345-54
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372(9637):449-56
   PubMed Web of Science ®Google Scholar
• Vickers MM, Choueiri TK, Rogers M, et al. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. Urology 2010;76(2):430-4
   PubMed Web of Science ®Google Scholar
• Levy A, Menard J, Albiges L, et al. Second line treatment of metastatic renal cell carcinoma: the Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients. Eur J Cancer 2013;49(8):1898-904
   PubMed Web of Science ®Google Scholar
• Park K, Lee J-L, Park I, et al. Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VE. Med Oncol 2012;29(5):3291-7
   PubMedGoogle Scholar
• Busch J, Seidel C, Kempkensteffen C, et al. Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors. Eur Urol 2011;60(6):1163-70
   PubMed Web of Science ®Google Scholar
• Busch J, Seidel C, Erber B, et al. Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma. Eur Urol 2013;64(1):62-70
   PubMedGoogle Scholar
• Wong MK, Yang H, Signorovitch JE, et al. Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a U.S. Medical Record Review. Curr Med Res Opin 2013;30(4):1-9
   PubMedGoogle Scholar
• Signorovitch JE, Vogelzang NJ, Pal SK, et al. Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United States. Curr Med Res Opin 2014;30(11):1-11
   PubMedGoogle Scholar
• Grassi P, Verzoni E, Porcu L, et al. Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factor. Future Oncol 2014;10(8):1361-72
   PubMedGoogle Scholar
• Harrison MR, Hirsch BR, George DJ, et al. Real-world outcomes in metastatic renal cell carcinoma: insights from a Joint Community-Academic Registry. J Oncol Pract 2014;10(2):e63-72
   PubMedGoogle Scholar
• Albiges L, Iacovelli R, Porta C, et al. Prognosis of patients with metastatic renal cell carcinoma (mRCC) with primary resistance to sunitinib: is there any active treatment? [Abstract 7143]. Euro J Cancer 2011.47(Suppl):529. Available from: http://new.ecco-org.eu/ecco_content/2011StockholmAbstractbook/index.html#/529/zoomed [Last accessed 27 June 2013]
   Google Scholar
• Seidel C, Busch J, Weikert S, et al. Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma - European Urology. Euro urologyrol 2012.48. Available from: http://www.europeanurology.com/article/S0959-8049(12)00185-2/abstract [Last accessed 23 May 2013]
   Google Scholar
• Grünwald V, Seidel C, Fenner M, et al. Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies. Br J Cancer 2011;105(11):1635-9
   PubMedGoogle Scholar
• Heng DYC, Xie W, Bjarnason GA, et al. A unified prognostic model for first- and second-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from a large international study. J Clin Oncol 2010;28(15 Suppl):abstract 4523
   Google Scholar
• Heng DYC, Lee J, Harshman LC, et al. An in-depth multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) that do not meet eligibility criteria for clinical trials. J Clin Oncol 2012;30(Suppl 5):abstract 387
   Google Scholar
• Kroeger N, Xie W, Lee J-L, et al. Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the international mRCC database consortium criteria. Cancer 2013;119(16):1-8
   PubMedGoogle Scholar
• Barthélémy P, Hoch B, Chevreau C, et al. mTOR inhibitors in advanced renal cell carcinomas: from biology to clinical practice. Crit Rev Oncol Hematol 2013;88(1):42-56
   PubMedGoogle Scholar
• National Institutes of Health. RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib - Study Results - ClinicalTrials.gov. ; 2013:ClinicalTrials.gov Identifier: NCT00410124. Available from: http://clinicaltrial.gov/ct2/show/results/NCT00410124?term=NCT00410124&rank=1&sect=X7015#outcome1 [Last accessed 3 October 2013]
   Google Scholar
• Blesius A, Beuselinck B, Chevreau C, et al. Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial. Clin Genitourin Cancer 2013;11(2):128-33
   PubMed Web of Science ®Google Scholar
• Booth CM, Eisenhauer EA. Progression-free survival: meaningful or simply measurable? J Clin Oncol 2012;30(10):1030-3
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Ferro M, Buonerba C. How to carry out retrospective studies in metastatic renal cell cancer: two caveats that should be avoided. Expert Rev Anticancer Ther 2012;12(3):331-3
   PubMed Web of Science ®Google Scholar
• Kaji AH, Schriger D, Green S. Looking through the retrospectoscope: reducing bias in emergency medicine chart review studies. Ann Emerg Med 2014;64(3):292-8
   PubMed Web of Science ®Google Scholar
• Worster A. Advanced statistics: understanding Medical Record Review (MRR) Studies. Acad Emerg Med 2004;11(2):187-92
   PubMed Web of Science ®Google Scholar
• Clark GM. Prognostic factors versus predictive factors: examples from a clinical trial of erlotinib. Mol Oncol 2008;1(4):406-12
   PubMed Web of Science ®Google Scholar
• Oldenhuis CN, Oosting SF, Gietema JA, et al. Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer 2008;44(7):946-53
   PubMed Web of Science ®Google Scholar